Hims & Hers Health Investors Urged to Lead Securities Fraud Lawsuit Efforts

Investors Alert: Hims & Hers Health, Inc. Securities Fraud Lawsuit

The Rosen Law Firm, a prominent name in securities litigation, has issued a reminder to investors of Hims & Hers Health, Inc. (NYSE: HIMS) regarding an important class action lawsuit. This notice specifically targets those who purchased Hims common stock during the period from April 29, 2025, to June 23, 2025. With a critical deadline of August 25, 2025, for potential lead plaintiffs to step forward, the firm is emphasizing the urgency of the situation.

Understanding the Class Action

If you bought shares of Hims during the specified class period, you may have a chance to join the lawsuit without incurring out-of-pocket expenses, courtesy of a contingency fee arrangement. The process is straightforward: Interested parties can either visit the Rosen Law Firm's designated webpage or simply reach out directly to Phillip Kim, Esq., for more information about how to become involved.

The Case's Background

The securities fraud lawsuit arises from allegations that the company and its representatives made false and misleading statements to investors. Specifically, the claim includes assertions that Hims was set to collaborate with Novo Nordisk A/S regarding the popular weight-loss drug, Wegovy, and that they misled shareholders about this partnership and the products offered.

Key allegations in the case emphasize that:
1. There was a purported long-term relationship with Novo that was underrepresented.
2. Hims would have been offering compounded semaglutide products under certain exceptions without proper disclosures.
3. Promises were made that branded Wegovy would be available alongside new options on their platform, which were not disclosed as intended.
4. Investors claim that positive statements about the partnership were misleading once the truth came to light.

Next Steps for Interested Investors

If you wish to join this lawsuit, the Rosen Law Firm provides easy access for shareholders looking to assert their rights. However, it's crucial to remember that no class has currently been certified. As such, investors are advised to engage with the legal avenues available if they wish to ensure their representation in potential future settlements.

Choose Your Representation Wisely

The firm cautions investors to choose legal representatives with established successes in securities litigation. In this instance, Rosen Law Firm has earned accolades for their proficiency in handling cases similar to these. With a proven track record, including having achieved notable settlements and recognition in the legal community, Rosen Law Firm serves as a reliable option for those requiring counsel in such matters.

To reiterate, investors keen on pursuing their claims or exploring additional information should either visit the firm's official website or reach out via phone or email for personalized support throughout this legal process.

Conclusion

As we approach August 25, 2025, affected Hims investors must act promptly to secure their position in what could become a significant legal challenge. Understanding the facts and seeking qualified legal representation are paramount for achieving any form of restitution.

For further updates and details regarding the progress of this case, interested parties are encouraged to follow Rosen Law Firm’s social media for real-time information.

Contact Information

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: 212-686-1060
Toll-Free: 866-767-3653
Email: [email protected]